Mycobacterial infections with Ruxolitinib: A retrospective pharmacovigilance review
ConclusionPatients on Ruxolitinib are at increased risk of developing MTB and AMI. Clinicians should be aware of this risk and consider screening patients for latent MTB prior to initiating Ruxolitinib.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Burns | Cancer & Oncology | Databases & Libraries | Legislation | Leukemia | Lymphoma | Myeloma | Study | Tuberculosis